Ghosn Marwan, Kourie Hampig Raphael, Abdayem Pamela, Antoun Joelle, Nasr Dolly
Marwan Ghosn, Hampig Raphael Kourie, Pamela Abdayem, Joelle Antoun, Dolly Nasr, Hematology-Oncology Department, Faculty Of Medicine, Saint Joseph University, Beirut, Lebanon.
World J Gastroenterol. 2015 Feb 28;21(8):2294-302. doi: 10.3748/wjg.v21.i8.2294.
Anal cancers (AC) are relatively rare tumors. Their incidence is increasing, particularly among men who have sex with other men due to widespread infection by human papilloma virus. The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage. In local and locally advanced AC, concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil (5-FU) is the current best treatment, while metastatic AC, chemotherapy with 5-FU and cisplatin remains the gold standard. There are no indications for induction or maintenance therapies in locally advanced tumors. Many novel strategies, such as targeted therapies, vaccination, immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC, with promising results in some indications.
肛管癌(AC)是相对罕见的肿瘤。其发病率正在上升,尤其是在男男性行为者中,这是由于人乳头瘤病毒的广泛感染所致。大多数肛管癌是鳞状细胞癌,并且根据分期进行治疗。在局部及局部晚期肛管癌中,基于丝裂霉素C和5-氟尿嘧啶(5-FU)的同步放化疗是目前最佳的治疗方法,而转移性肛管癌,以5-FU和顺铂进行化疗仍是金标准。对于局部晚期肿瘤,没有进行诱导或维持治疗的指征。许多新策略,如靶向治疗、疫苗接种、免疫治疗和光动力治疗正在用于肛管癌治疗的临床试验中,在某些指征方面取得了有前景的结果。